Literature DB >> 27611213

APOBEC3G governs the generation of truncated AATF protein to ensure oncogenic transformation.

Shaveta Sharma1, Anuradha Garg1, Rakesh S Dhanda1, Deepak Kaul1.   

Abstract

The oncogenic potential of Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G) was recently appreciated by the finding that revealed its ability to downregulate Kruppel-like factor 4 (KLF4) gene translation through its affinity for 3'UTR of KLF4 mRNA. Keeping in view the fact that KLF4 is known to repress apoptosis antagonizing transcription factor (AATF) gene expression, the present study employed stem cells as archetype model to explore the effect of APOBEC3G over-expression upon AATF gene expression within these cells as well as on the genes involved in oncogenic transformation. Such a study revealed that APOBEC3G had the ability to bind AATF mRNA within its third exon to facilitate the generation of truncated 23 kDa AATF translation product which, in turn, had the inherent capacity to be the crucial mediator of APOBEC3G induced oncogenic transformation within such cells.
© 2016 International Federation for Cell Biology.

Entities:  

Keywords:  APOBEC3G; CD34+ stem cells; oncogenes; truncated-AATF

Mesh:

Substances:

Year:  2016        PMID: 27611213     DOI: 10.1002/cbin.10681

Source DB:  PubMed          Journal:  Cell Biol Int        ISSN: 1065-6995            Impact factor:   3.612


  2 in total

Review 1.  Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like family genes activation and regulation during tumorigenesis.

Authors:  Jianlong Gao; Hani Choudhry; Wei Cao
Journal:  Cancer Sci       Date:  2018-06-28       Impact factor: 6.716

2.  APOBEC3G acts as a therapeutic target in mesenchymal gliomas by sensitizing cells to radiation-induced cell death.

Authors:  Yu Wang; Shaofang Wu; Siyuan Zheng; Shuzhen Wang; Arjun Wali; Ravesanker Ezhilarasan; Erik P Sulman; Dimpy Koul; W K Alfred Yung
Journal:  Oncotarget       Date:  2017-04-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.